Taysha Gene Therapies (TSHA)
(Delayed Data from NSDQ)
$3.14 USD
+0.03 (0.96%)
Updated May 16, 2024 04:00 PM ET
After-Market: $3.14 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth B Momentum C VGM
Industry / Sector Report
Industry : Medical - Generic Drugs
Zacks Industry Rank
Top 21% (52 out of 250)Zacks Sector Rank
Top 25% (4 out of 16)Recommendations and Estimates
Company | Industry | SP500 | |
---|---|---|---|
Average Recommendation (1=Buy, 5=Sell) | 1.09 | 1.42 | 9.99 |
Current Quarter Estimate | -0.11 | 1.25 | 57.00 |
Year Ago Quarter Estimate | -0.38 | -4.28 | 52.54 |
Next Quarter Estimate | -0.10 | 1.37 | 61.00 |
Next Year Estimate | -0.46 | 7.08 | 270.00 |
Growth Rates
Company | Industry | SP500 | |
---|---|---|---|
This Year | 59.38 | 19.40 | 15.67 |
Next Year | -17.95 | 13.70 | 9.31 |
Last 5 Years | NA | 0.10 | 8.10 |
Next 5 Years | NA | 8.90 | NA |
Financials
Company | Industry | |
---|---|---|
Price/Earnings (TTM) | NA | 1.64 |
Price/Book (MRQ) | 7.76 | 1.13 |
Price/Cash Flow (MRFY) | NA | 10.62 |
Dividend Yield | 0.00% | 0.00% |
Net Profit Margin (TTM) | -833.60% | -2.88% |
Return on Equity (TTM) | NA | -1.68% |
Debt to Equity (MRQ) | NA | 1.05 |
MRQ = Most Recent Quarter
TTM = Trailing Twelve Months
MRFY = Most Recent Fiscal Year
Note: Company and S&P 500 ratios relating to share price calculated daily; all others calculated weekly or in accordance with company earnings announcement. Industry medians calculated weekly.